Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Teva Pharmaceutical Industries ADR
(NY:
TEVA
)
13.81
+0.56 (+4.23%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Teva Pharmaceutical Industries ADR
< Previous
1
2
3
4
5
6
Next >
Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease
October 18, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reaches Agreement With Arkansas to Settle the State’s Price Fixing Claims
October 07, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022
October 06, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Largest-Ever Trial to Collect Information from Patients and Physicians About TD, its Impact and Progression Over Time, and Evaluate Treatment-Related Outcomes
October 06, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reaches Agreement With Georgia to Settle the State’s Price Fixing Claims
September 30, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Launches Honestly HD Website to Provide People Living With Huntington’s Disease (HD) Information, Inspiration and Resources on HD Chorea
September 26, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Studies Show Effectiveness of AJOVY®▼ (fremanezumab) for Treatment of Migraine in Patients With Co-morbid Depression
September 08, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
CONNECT1 Study Published in Journal of Allergy and Clinical Immunology: In Practice Evaluates the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder and Digihaler System to Help Improve Asthma Management
September 07, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022
August 29, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
European Commission grants marketing authorization for Ranivisio▼®* (ranibizumab), a biosimilar to Lucentis®**, for age-related macular degeneration (AMD) the most common cause of blindness in developed countries
August 29, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Is Sanofi A Buy, Despite Recent Stumbles?
August 19, 2022
Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Volume Surges Spark Turnarounds for These 3 Stocks
August 09, 2022
There are countless historical chart examples of high volume moves that mark the beginning of sustained rallies or slumps. Let’s tune into a few examples.
Via
MarketBeat
Topics
Lawsuit
Exposures
Financial
Legal
Teva Reports Second Quarter 2022 Financial Results
July 26, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reaches Agreement With San Francisco to Settle Opioid-Related Claims
July 12, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Appointment of New Global R&D and Chief Medical Officer
July 01, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Host Conference Call to Discuss Second Quarter 2022 Financial Results at 8 a.m. ET on July 27, 2022
June 29, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab)
June 24, 2022
From
Teva Pharmaceutical Industries Ltd.
Via
Business Wire
Teva Announces Settlement with Aurobindo Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
June 09, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
New Real-World Data Evaluating AJOVY® (fremanezumab-vfrm) Injection Use in Patients With Migraine Presented at 2022 American Headache Society Annual Meeting
June 09, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting
June 09, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Partner to Advance Access to Behavioral Health Services
June 08, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reaches Agreement With West Virginia to Settle the State’s Opioid-Related Claims
May 25, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting
May 23, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼
May 17, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting
May 17, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges
May 17, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at American Thoracic Society 2022 Annual Meeting
May 12, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targets and Strengthened ESG Governance Structure
May 10, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reports First Quarter 2022 Financial Results
May 03, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
May 02, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.